News And Updates

Cosmetic or Drug? How Claims on Labels, Websites and Social Media Draw FDA Warning Letters

A cream that moisturizes is a cosmetic. Sold to clear acne, regrow hair or build collagen, it is an unapproved drug. What FDA's 2026 warning letters show and how to review your claims.

Return to Top

Whether a product is a cosmetic or a drug under federal law turns on what it is intended to do, and FDA judges intent mostly by what the company says about it. A cream sold to moisturize is a cosmetic. The same cream sold to "eliminate acne" or "promote collagen production" is a drug. If it does not fit an over-the-counter (OTC) drug monograph, the set of FDA rules that lets certain nonprescription drugs be sold without individual approval, and has no approved application, it is an unapproved new drug that cannot lawfully be sold.

Where the line is

The Federal Food, Drug, and Cosmetic Act (FD&C Act) defines cosmetics as products for cleansing, beautifying, promoting attractiveness or altering the appearance. Drugs are products intended to diagnose, cure, mitigate, treat or prevent disease, or to affect the structure or any function of the body. FDA's guidance is explicit that the skin is part of the body, so a claim to change how skin works makes the product a drug even if it also changes how skin looks. FDA's own examples include restoring hair growth, reducing cellulite, increasing or decreasing melanin production and regenerating cells. Its warning letters on products sold as cosmetics add acne treatment, stretch mark and wrinkle removal, dandruff treatment and eyelash growth.

In our experience the words "anti-aging" are rarely the problem on their own. What follows them is. "Reduces the look of fine lines" describes appearance. "Rebuilds collagen" or "repairs skin at the cellular level" describes a change in structure. There is no safe middle ground either: FDA says the law does not recognize a category called "cosmeceuticals."

Some products are legitimately both, such as antidandruff shampoo, antiperspirant deodorant and a moisturizer with SPF. Those must meet both sets of rules, including a Drug Facts label, drug establishment registration and listing, and drug current good manufacturing practice (CGMP) requirements. We will cover sunscreens separately.

What FDA has done this year

The 2026 letters follow two patterns. In May, FDA's drug center warned two online sellers of skin creams whose websites promised to remove acne, melasma and dark spots; FDA testing had also found mercury in the products. Letters to manufacturers in April, July and September paired inspection findings with label claims: acne and rosacea "stoppers," an eczema balm, an acne body wash containing active ingredients the acne monograph does not allow, and an SPF face cream promising to promote collagen production. Each letter asked for a written response within 15 business days. At the border, FDA's Import Alert 66-41, updated November 17, 2026, allows detention without examination of products that look like cosmetics but carry claims that make them unapproved new drugs.

How to review your claims

FDA looks beyond the label to advertising, websites and other promotional material, to ingredients with a well-known therapeutic use, and to what consumers understand the product to do. We treat a brand's own social media posts, influencer content it directs or reposts, marketplace listings and the product name itself as part of the same record. A name like "Acne Killer" is a claim.

Start by collecting every place each product is described. Flag verbs that describe treating a condition or changing the body, such as heals, cures, regrows, repairs, stimulates and prevents. Then either rewrite to appearance language or decide deliberately to sell the product as a drug, with a monograph-compliant formula, a Drug Facts label and a registered drug facility. Repeat the review whenever marketing launches new copy. Keep in mind that the Federal Trade Commission (FTC) separately requires advertising claims to be truthful and supported.

How MDRXLaw can help

We review cosmetic labels, websites and social media copy for drug claims, advise brands deciding whether a product belongs in the OTC drug framework, and respond to FDA warning letters and import detentions. To have your claims reviewed, contact us at info@mdrxlaw.com or 212-668-0200.

Sources: FDA, Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?); FDA, Cosmetics Labeling Claims; FDA, Warning Letters Address Drug Claims Made for Products Marketed as Cosmetics; FDA, Import Alert 66-41. This alert is for general information and is not legal advice.

Attorney Advertising. Prior results do not guarantee a similar outcome. This website is for general information only and is not legal advice. Viewing it or contacting the firm does not create an attorney-client relationship, and you should not send confidential information until the firm has confirmed it represents you.

Privacy Policy · Opt out of targeted ads